KLRS Stock — Kalaris Therapeutics, Inc.

Kalaris Therapeutics, Inc. (KLRS)

Updated October 16, 2026.

KLRS is a Stock. Total return is -99.7% over the past 6.2 years, 256.2 points behind SPY at 156.5%.

Kalaris Therapeutics is a clinical-stage biopharmaceutical company developing treatments for retinal diseases, with its lead program being TH103, an anti-VEGF drug in Phase 1b/2 testing for neovascular age-related macular degeneration and other retinal conditions. As an early-stage biotech company, it does not currently have an established distribution pattern. The stock appeals primarily to investors with high risk tolerance seeking exposure to clinical-stage drug development, rather than those focused on income generation.

KLRS performance versus SPY

Price and return data through 2026-10-16.

Total return is -99.7% over the past 6.2 years, 256.2 points behind SPY at 156.5%. Over the past year its total return — price change plus distributions reinvested — is -58.2%. Its deepest 1-year drawdown was 81.8%.

KLRS key facts

Asset type

Stock

Asset class

Equity

Inception date

07/30/2020

Distribution frequency

None

Last close

$2.00 (as of 2026-10-16)

Market cap

$47,609,962

Average volume

58400.0

Payout ratio

0.0%

EPS

$-2.02

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

KLRS risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 81.8%.

Who may consider KLRS — and who may not

It is a weaker fit for investors who need monthly cash flow (KLRS does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on KLRS

• All tickers starting with K

Tagged: Healthcare.

Frequently asked questions